Shopping Cart 0
Cart Subtotal
AED 0

Bioxyne Ltd (BXN) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 1376
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Bioxyne Ltd (BXN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd Key Recent Developments

Oct 29,2018: Bioxyne: Quarterly report for the period ended 30 September 2018

Jul 27,2018: Bioxyne: Quarterly report for the period ended 30 June 2018

May 01,2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett

Apr 27,2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018

Feb 15,2018: Bioxyne: Resignation of Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Bioxyne Ltd-Key Facts 5

Bioxyne Ltd-Key Employees 6

Bioxyne Ltd-Key Employee Biographies 7

Bioxyne Ltd-Major Products and Services 8

Bioxyne Ltd-History 9

Bioxyne Ltd-Company Statement 10

Bioxyne Ltd-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Company Overview 12

Bioxyne Ltd-Business Description 13

Bioxyne Ltd-SWOT Analysis 14

SWOT Analysis-Overview 14

Bioxyne Ltd-Strengths 14

Bioxyne Ltd-Weaknesses 15

Bioxyne Ltd-Opportunities 16

Bioxyne Ltd-Threats 17

Bioxyne Ltd-Key Competitors 18

Section 3-Company Financial Ratios 19

Financial Ratios-Annual Ratios 19

Performance Chart 22

Financial Performance 22

Financial Ratios-Interim Ratios 23

Financial Ratios-Ratio Charts 24

Section 4-Company's Lifesciences Financial Deals and Alliances 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

Bioxyne Ltd, Recent Deals Summary 27

Section 5-Company's Recent Developments 28

Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 28

Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 29

May 01, 2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett 30

Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 31

Feb 15, 2018: Bioxyne: Resignation of Director 32

Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 33

Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 34

Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 35

Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 36

Section 6-Appendix 38

Methodology 38

Ratio Definitions 38

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Bioxyne Ltd, Performance Chart (2014-2018) 22

Bioxyne Ltd, Ratio Charts 24

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26


List Of Table

List of Tables

Bioxyne Ltd, Key Facts 5

Bioxyne Ltd, Key Employees 6

Bioxyne Ltd, Key Employee Biographies 7

Bioxyne Ltd, Major Products and Services 8

Bioxyne Ltd, History 9

Bioxyne Ltd, Subsidiaries 11

Bioxyne Ltd, Key Competitors 18

Bioxyne Ltd, Annual Ratios 19

Bioxyne Ltd, Annual Ratios (Cont...1) 20

Bioxyne Ltd, Annual Ratios (Cont...2) 21

Bioxyne Ltd, Interim Ratios 23

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

Bioxyne Ltd, Recent Deals Summary 27

Currency Codes 38

Capital Market Ratios 38

Equity Ratios 39

Profitability Ratios 39

Cost Ratios 40

Liquidity Ratios 40

Leverage Ratios 41

Efficiency Ratios 41

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Bioxyne Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Probiotics Australia Pty Ltd

Probiotec Ltd

Giaconda Ltd

BioCeuticals Pty Ltd

Amplia Therapeutics Ltd

Bioxyne Ltd (BXN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd Key Recent Developments

Oct 29,2018: Bioxyne: Quarterly report for the period ended 30 September 2018

Jul 27,2018: Bioxyne: Quarterly report for the period ended 30 June 2018

May 01,2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett

Apr 27,2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018

Feb 15,2018: Bioxyne: Resignation of Director

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Bioxyne Ltd-Key Facts 5

Bioxyne Ltd-Key Employees 6

Bioxyne Ltd-Key Employee Biographies 7

Bioxyne Ltd-Major Products and Services 8

Bioxyne Ltd-History 9

Bioxyne Ltd-Company Statement 10

Bioxyne Ltd-Locations And Subsidiaries 11

Head Office 11

Other Locations & Subsidiaries 11

Section 2-Company Analysis 12

Company Overview 12

Bioxyne Ltd-Business Description 13

Bioxyne Ltd-SWOT Analysis 14

SWOT Analysis-Overview 14

Bioxyne Ltd-Strengths 14

Bioxyne Ltd-Weaknesses 15

Bioxyne Ltd-Opportunities 16

Bioxyne Ltd-Threats 17

Bioxyne Ltd-Key Competitors 18

Section 3-Company Financial Ratios 19

Financial Ratios-Annual Ratios 19

Performance Chart 22

Financial Performance 22

Financial Ratios-Interim Ratios 23

Financial Ratios-Ratio Charts 24

Section 4-Company's Lifesciences Financial Deals and Alliances 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

Bioxyne Ltd, Recent Deals Summary 27

Section 5-Company's Recent Developments 28

Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 28

Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 29

May 01, 2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett 30

Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 31

Feb 15, 2018: Bioxyne: Resignation of Director 32

Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 33

Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 34

Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 35

Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 36

Section 6-Appendix 38

Methodology 38

Ratio Definitions 38

About GlobalData 42

Contact Us 42

Disclaimer 42


List Of Figure

List of Figures

Bioxyne Ltd, Performance Chart (2014-2018) 22

Bioxyne Ltd, Ratio Charts 24

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 26


List Of Table

List of Tables

Bioxyne Ltd, Key Facts 5

Bioxyne Ltd, Key Employees 6

Bioxyne Ltd, Key Employee Biographies 7

Bioxyne Ltd, Major Products and Services 8

Bioxyne Ltd, History 9

Bioxyne Ltd, Subsidiaries 11

Bioxyne Ltd, Key Competitors 18

Bioxyne Ltd, Annual Ratios 19

Bioxyne Ltd, Annual Ratios (Cont...1) 20

Bioxyne Ltd, Annual Ratios (Cont...2) 21

Bioxyne Ltd, Interim Ratios 23

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 25

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 26

Bioxyne Ltd, Recent Deals Summary 27

Currency Codes 38

Capital Market Ratios 38

Equity Ratios 39

Profitability Ratios 39

Cost Ratios 40

Liquidity Ratios 40

Leverage Ratios 41

Efficiency Ratios 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Bioxyne Ltd, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Probiotics Australia Pty Ltd

Probiotec Ltd

Giaconda Ltd

BioCeuticals Pty Ltd

Amplia Therapeutics Ltd